BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38049961)

  • 21. Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model.
    Lozovaya N; Gataullina S; Tsintsadze T; Tsintsadze V; Pallesi-Pocachard E; Minlebaev M; Goriounova NA; Buhler E; Watrin F; Shityakov S; Becker AJ; Bordey A; Milh M; Scavarda D; Bulteau C; Dorfmuller G; Delalande O; Represa A; Cardoso C; Dulac O; Ben-Ari Y; Burnashev N
    Nat Commun; 2014 Aug; 5():4563. PubMed ID: 25081057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
    Zhang B; McDaniel SS; Rensing NR; Wong M
    PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A brain proteomic investigation of rapamycin effects in the
    Wesseling H; Elgersma Y; Bahn S
    Mol Autism; 2017; 8():41. PubMed ID: 28775826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model.
    Koene LMC; van Grondelle SE; Proietti Onori M; Wallaard I; Kooijman NHRM; van Oort A; Schreiber J; Elgersma Y
    Ann Clin Transl Neurol; 2019 Jul; 6(7):1273-1291. PubMed ID: 31353861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
    Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
    Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
    Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
    Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
    Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
    J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bama miniature pig model of monoallelic TSC1 mutation for human tuberous sclerosis complex.
    Li X; Hu T; Liu J; Fang B; Geng X; Xiong Q; Zhang L; Jin Y; Liu X; Li L; Wang Y; Li R; Bai X; Yang H; Dai Y
    J Genet Genomics; 2020 Dec; 47(12):735-742. PubMed ID: 33612456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells.
    Chiaradia E; Miller I; Renzone G; Tognoloni A; Polchi A; De Marco F; Tancini B; Scaloni A; Magini A
    J Proteomics; 2023 Jul; 283-284():104928. PubMed ID: 37207814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synaptic hyperexcitability of cytomegalic pyramidal neurons contributes to epileptogenesis in tuberous sclerosis complex.
    Wu X; Sosunov AA; Lado W; Teoh JJ; Ham A; Li H; Al-Dalahmah O; Gill BJA; Arancio O; Schevon CA; Frankel WN; McKhann GM; Sulzer D; Goldman JE; Tang G
    Cell Rep; 2022 Jul; 40(3):111085. PubMed ID: 35858542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tuberous sclerosis complex.
    Hasbani DM; Crino PB
    Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seizure reduction in TSC2-mutant mouse model by an mTOR catalytic inhibitor.
    Dhamne SC; Modi ME; Gray A; Bonazzi S; Craig L; Bainbridge E; Lalani L; Super CE; Schaeffer S; Capre K; Lubicka D; Liang G; Burdette D; McTighe SM; Gurnani S; Vermudez SAD; Curtis D; Wilson CJ; Hameed MQ; D'Amore A; Rotenberg A; Sahin M
    Ann Clin Transl Neurol; 2023 Oct; 10(10):1790-1801. PubMed ID: 37545094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis.
    McMahon J; Huang X; Yang J; Komatsu M; Yue Z; Qian J; Zhu X; Huang Y
    J Neurosci; 2012 Nov; 32(45):15704-14. PubMed ID: 23136410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
    Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
    Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
    Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
    Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
    Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
    Mizuguchi M; Ohsawa M; Kashii H; Sato A
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
    Nguyen LH; Mahadeo T; Bordey A
    J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing Ca
    Hisatsune C; Shimada T; Miyamoto A; Lee A; Yamagata K
    J Neurosci; 2021 Sep; 41(39):8134-8149. PubMed ID: 34417327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.